Screener
Veradermics MANE Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Veradermics’s 10-K, filed March 30, 2026.
- Filed
- Mar 30, 2026, 5:35 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001827635-26-000013
| (in thousands, except share and per share amounts) | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Other income (expenses): | ||
| Interest income | 1,562 | 481 |
| Other income | 790 | 394 |
| Interest expense | — | (585) |
| Total other income, net | 2,352 | 290 |
| Loss before income taxes | (69,995) | (26,488) |
| Income tax benefit | — | — |
| Net loss | $(69,995) | $(26,488) |
Item 16. Form 10-K Summary
FAQ
- What is Veradermics's interest expense?
- Veradermics (MANE) reported interest expense of $0 in Q4 2025.
- How has Veradermics's interest expense changed year-over-year?
- Veradermics's interest expense decreased by 100.0% year-over-year, from $146.25K to $0.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Veradermics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude